{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:22:30Z","timestamp":1777868550604,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordination for the improvement of Higher Education Personnel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejphar.2026.178877","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T19:47:54Z","timestamp":1776282474000},"page":"178877","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Quizartinib-induced resistance drives clonal emergence of MV4-11\u00a0cells with molecular alterations enabling multidrug antileukemic escape"],"prefix":"10.1016","volume":"1023","author":[{"given":"Livia Bassani Lins","family":"de Miranda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keli","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3302-4311","authenticated-orcid":false,"given":"Diego A.","family":"Pereira-Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3388-0369","authenticated-orcid":false,"given":"Juan Luiz","family":"Coelho-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Tomaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz Gustavo Ferreira","family":"Cortez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina de Franca Basto","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael Lucas Muniz","family":"Guedes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo Vidal","family":"Campregher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3946-1368","authenticated-orcid":false,"given":"Dominique","family":"Sternadt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo Magalh\u00e3es","family":"Rego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiola","family":"Traina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Jacob","family":"Schuringa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2937-8109","authenticated-orcid":false,"given":"Jo\u00e3o Agostinho","family":"Machado-Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.178877_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-021-01111-4","article-title":"MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies","volume":"14","author":"Ahmadi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejphar.2026.178877_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2025.107724","article-title":"Impact of FLT3 inhibitors on the outcomes of FLT3-ITD mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant: a systematic review and meta-analysis","volume":"155","author":"Amin","year":"2025","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejphar.2026.178877_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/jpm15090431","article-title":"Metabolic signature of FLT3-Mutated AML: clinical and therapeutic implications","volume":"15","author":"Banella","year":"2025","journal-title":"J Pers Med"},{"key":"10.1016\/j.ejphar.2026.178877_bib4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/cdd.2017.180","article-title":"Why are there hotspot mutations in the TP53 gene in human cancers?","volume":"25","author":"Baugh","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejphar.2026.178877_bib5","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood.V120.21.677.677","article-title":"Phase I\/II trial of the MEK1\/2 inhibitor trametinib (GSK1120212) in relapsed\/refractory myeloid malignancies: evidence of activity in patients with RAS mutation-positive disease","volume":"120","author":"Borthakur","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2026.178877_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fonc.2016.00021","article-title":"Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy","volume":"6","author":"Bykov","year":"2016","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2026.178877_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1478-811X-8-31","article-title":"PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration","volume":"8","author":"Chaitanya","year":"2010","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejphar.2026.178877_bib8","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","article-title":"Mutant p53 in cancer: from molecular mechanism to therapeutic modulation","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2026.178877_bib9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2026.178877_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104384","article-title":"Tyrosine kinase inhibitors in cancers: treatment optimization - part I","volume":"199","author":"Combarel","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejphar.2026.178877_bib11","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2026.178877_bib12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2009-06-227363","article-title":"SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia","volume":"115","author":"Cristobal","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2026.178877_bib13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2026.178877_bib14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-022-00687-5","article-title":"Resistance to targeted therapies: delving into FLT3 and IDH","volume":"12","author":"Desikan","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejphar.2026.178877_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102154","article-title":"MYC as a target for cancer treatment","volume":"94","author":"Duffy","year":"2021","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejphar.2026.178877_bib16","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00018-023-04729-4","article-title":"Receptor tyrosine kinase inhibitors in cancer","volume":"80","author":"Ebrahimi","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejphar.2026.178877_bib17","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2026.178877_bib18","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1200\/JCO.22.01386","article-title":"A new dancing partner for venetoclax: Gilteritinib","volume":"40","author":"Fathi","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.178877_bib19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178877_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16061091","article-title":"Venetoclax resistance in acute myeloid leukemia","volume":"16","author":"Garciaz","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejphar.2026.178877_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1655005","article-title":"Metabolic reprogramming and immune regulation in acute myeloid leukemia","volume":"16","author":"Hao","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.178877_bib22","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022061","article-title":"TGF-Beta signaling from receptors to smads","volume":"8","author":"Hata","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.ejphar.2026.178877_bib23","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/s41431-021-00888-9","article-title":"Clinical delineation of SETBP1 haploinsufficiency disorder","volume":"29","author":"Jansen","year":"2021","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ejphar.2026.178877_bib24","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood.2021014241","article-title":"Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1","volume":"140","author":"Janssen","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2026.178877_bib25","doi-asserted-by":"crossref","first-page":"E364","DOI":"10.1002\/ajh.27096","article-title":"The FLT3(N701K) mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib","volume":"98","author":"Joshi","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejphar.2026.178877_bib26","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejphar.2026.178877_bib27","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/ejh.14044","article-title":"Prognostic value of the mutation types and dynamics of FLT3-ITD in acute myeloid leukemia","volume":"111","author":"Koo","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ejphar.2026.178877_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041537","article-title":"Overcoming resistance to FLT3 inhibitors in the treatment of FLT3-Mutated AML","volume":"21","author":"Lam","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178877_bib29","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1111\/1759-7714.14703","article-title":"Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification","volume":"13","author":"Lin","year":"2022","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.ejphar.2026.178877_bib30","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.ejphar.2026.178877_bib31","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12943-025-02455-y","article-title":"Novel molecular mechanisms of FLT3 deregulation: from the acute myeloid leukemia experience to therapeutic insights in acute lymphoblastic leukemia","volume":"24","author":"Lo Schiavo","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejphar.2026.178877_bib32","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/leu.2010.6","article-title":"gammaH2AX: a sensitive molecular marker of DNA damage and repair","volume":"24","author":"Mah","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2026.178877_bib33","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejphar.2026.178877_bib34","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/bloodadvances.2019000986","article-title":"Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736","volume":"4","author":"Moore","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejphar.2026.178877_bib35","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2147\/OTT.S479519","article-title":"Anti-tumor effects of gilteritinib on FLT3 mutations: insights into resistance mechanisms in Ba\/F3 cell models","volume":"18","author":"Nakazawa","year":"2025","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejphar.2026.178877_bib36","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178877_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104424","article-title":"Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy","volume":"201","author":"Ruglioni","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejphar.2026.178877_bib38","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-Mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.178877_bib39","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.1007\/s00277-024-06089-w","article-title":"All-trans retinoic acid potentiates cell death induced by quizartinib in acute myeloid leukemia with FLT3-ITD mutations","volume":"103","author":"Sanchez-Mendoza","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ejphar.2026.178877_bib40","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cell.2006.11.042","article-title":"Essential role for nuclear PTEN in maintaining chromosomal integrity","volume":"128","author":"Shen","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2026.178877_bib41","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/leu.2015.165","article-title":"FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors","volume":"29","author":"Smith","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2026.178877_bib42","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178877_bib43","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2147\/OTT.S384293","article-title":"Therapeutic targeting of FLT3 in acute myeloid leukemia: current status and novel approaches","volume":"15","author":"Tecik","year":"2022","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejphar.2026.178877_bib44","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-024-01899-w","article-title":"Therapeutic advances of targeting receptor tyrosine kinases in cancer","volume":"9","author":"Tomuleasa","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ejphar.2026.178877_bib45","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/CCO.0000000000001094","article-title":"Advances in the pathogenesis of FLT3 -mutated acute myeloid leukemia and targeted treatments","volume":"36","author":"Travaglini","year":"2024","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.ejphar.2026.178877_bib46","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12935-023-03000-x","article-title":"Combination strategies to overcome drug resistance in FLT(+) acute myeloid leukaemia","volume":"23","author":"Yang","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejphar.2026.178877_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2023.107889","article-title":"Synergy and antagonism between azacitidine and FLT3 inhibitors","volume":"169","author":"Yang","year":"2024","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.ejphar.2026.178877_bib48","article-title":"Resistance to FLT3 inhibitors involves different molecular mechanisms and reduces new DNA synthesis","volume":"41","author":"Yang","year":"2025","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.ejphar.2026.178877_bib49","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12935-021-01856-5","article-title":"Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib","volume":"21","author":"Yang","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejphar.2026.178877_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102271","article-title":"Combined anti-leukemic effect of gilteritinib and GSK-J4 in FLT3-ITD(+) acute myeloid leukemia","volume":"52","author":"Zhou","year":"2025","journal-title":"Transl. Oncol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926003596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926003596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:05:31Z","timestamp":1777550731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926003596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":50,"alternative-id":["S0014299926003596"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178877","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quizartinib-induced resistance drives clonal emergence of MV4-11\u00a0cells with molecular alterations enabling multidrug antileukemic escape","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178877","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"178877"}}